Sage Therapeutics (SAGE) News Today → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free SAGE Stock Alerts $12.01 +0.30 (+2.56%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 9:01 PM | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sage Therapeutics, Inc. - SAGEMay 14 at 8:37 PM | finance.yahoo.comSage Therapeutics, Inc. (SAGE)May 7, 2024 | businesswire.comSage Therapeutics to Participate in Upcoming May Investor ConferencesMay 7, 2024 | americanbankingnews.comSage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Recommendation of "Hold" by BrokeragesMay 6, 2024 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Trading Down 4.2%Sage Therapeutics (NASDAQ:SAGE) Trading Down 4.2%May 6, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGEMay 1, 2024 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Price Target Cut to $28.00 by Analysts at JPMorgan Chase & Co.JPMorgan Chase & Co. lowered their target price on shares of Sage Therapeutics from $29.00 to $28.00 and set an "overweight" rating on the stock in a research note on Wednesday.April 30, 2024 | finance.yahoo.comSage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call TranscriptApril 30, 2024 | marketbeat.comabrdn plc Invests $1.40 Million in Sage Therapeutics, Inc. (NASDAQ:SAGE)abrdn plc purchased a new stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 64,801 shares of the biopharmaceutical company's stock, valued at approximApril 28, 2024 | finance.yahoo.comEarnings Update: Sage Therapeutics, Inc. (NASDAQ:SAGE) Just Reported And Analysts Are Boosting Their EstimatesApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGEApril 26, 2024 | finance.yahoo.comSage Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsApril 26, 2024 | markets.businessinsider.comBalancing Opportunity and Risk: Hold Rating on SAGE Therapeutics Amidst High-Stakes Catalysts and Financial ReassessmentApril 26, 2024 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Posts Quarterly Earnings Results, Misses Expectations By $0.17 EPSSage Therapeutics (NASDAQ:SAGE - Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.63) by ($0.17). The firm had revenue of $7.90 million for the quarter, compared to analysts' expectations of $5.26 million. Sage Therapeutics had a negative net margin of 626.32% and a negative return on equity of 54.41%. Sage Therapeutics's revenue was up 139.4% on a year-over-year basis. During the same period in the prior year, the firm posted ($2.46) EPS.April 26, 2024 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Price Target Cut to $25.00 by Analysts at HC WainwrightHC Wainwright cut their price target on shares of Sage Therapeutics from $28.00 to $25.00 and set a "neutral" rating for the company in a research note on Friday.April 26, 2024 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) to Post FY2025 Earnings of ($7.01) Per Share, William Blair ForecastsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Stock analysts at William Blair issued their FY2025 EPS estimates for shares of Sage Therapeutics in a report issued on Thursday, April 25th. William Blair analyst T. Lugo forecasts that the biopharmaceutical company will post earnings per shaApril 26, 2024 | markets.businessinsider.comSAGE Therapeutics’ Zurzuvae Sales Exceed Expectations but Uncertainties Prompt Hold RatingApril 25, 2024 | markets.businessinsider.comHold Rating on SAGE Therapeutics Amid Limited Revenue Prospects and Pipeline UncertaintyApril 25, 2024 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Stock Price Up 5.5%Sage Therapeutics (NASDAQ:SAGE) Trading 5.5% HigherApril 25, 2024 | investorplace.comSAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024April 25, 2024 | seekingalpha.comSage Therapeutics, Inc. 2024 Q1 - Results - Earnings Call PresentationApril 25, 2024 | markets.businessinsider.comSAGE Therapeutics, Inc. Q1 Loss decreases, but misses estimatesApril 25, 2024 | finance.yahoo.comSage Therapeutics Inc (SAGE) Q1 2024 Earnings: Mixed Results Amidst Pipeline ProgressApril 25, 2024 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Earns Hold Rating from Needham & Company LLCNeedham & Company LLC reissued a "hold" rating on shares of Sage Therapeutics in a research note on Thursday.April 25, 2024 | businesswire.comSage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business ProgressApril 24, 2024 | markets.businessinsider.comHere's what to expect from Sage Therapeutics's earnings reportApril 19, 2024 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Cut to "Sell" at StockNews.comStockNews.com cut Sage Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday.April 19, 2024 | marketbeat.comQ1 2024 Earnings Estimate for Sage Therapeutics, Inc. (NASDAQ:SAGE) Issued By WedbushSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Wedbush decreased their Q1 2024 earnings per share estimates for shares of Sage Therapeutics in a report released on Wednesday, April 17th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will earn ($1.92) per share fApril 18, 2024 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Trading Up 6.2%Sage Therapeutics (NASDAQ:SAGE) Stock Price Up 6.2%April 18, 2024 | msn.comB of A Securities Downgrades Sage Therapeutics (SAGE)April 18, 2024 | markets.businessinsider.comIn-Depth Examination Of 9 Analyst Recommendations For Sage TherapeuticsApril 18, 2024 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Given Hold Rating at Needham & Company LLCNeedham & Company LLC reaffirmed a "hold" rating on shares of Sage Therapeutics in a research note on Thursday.April 17, 2024 | msn.comSage Therapeutics stock plunges 20 percent after Parkinson’s drug fails studyApril 17, 2024 | marketbeat.comWedbush Reiterates Neutral Rating for Sage Therapeutics (NASDAQ:SAGE)Wedbush reiterated a "neutral" rating and set a $24.00 price objective on shares of Sage Therapeutics in a research report on Wednesday.April 17, 2024 | benzinga.comNeurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's DataApril 17, 2024 | msn.comBofA downgrades Sage to underperform, cites failed Parkinson's studyApril 17, 2024 | markets.businessinsider.comNasdaq Down Over 1%; Sage Therapeutics Shares PlungeApril 17, 2024 | finance.yahoo.comSage Stock Collapses To Record Low After Parkinson's Drug Misses Its MarkApril 17, 2024 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Shares Gap Down to $15.63Sage Therapeutics (NASDAQ:SAGE) Shares Gap Down to $15.63April 17, 2024 | investors.comSage Therapeutics Hammered After Parkinson's Drug Misses The MarkApril 17, 2024 | marketwatch.comSage Therapeutics Stops Further Development of Dalzanemdor in Parkinson's DiseaseApril 17, 2024 | marketwatch.comSage Therapeutics Shares Sink Premarket After Setback in Development of DalzanemdorApril 17, 2024 | markets.businessinsider.comSage Therapeutics' Dalzanemdor Phase 2 Study Fails To Meet Primary EndpointApril 17, 2024 | msn.comSage drops after mid-stage setback for Parkinson’s disease candidateApril 17, 2024 | reuters.comSage Therapeutics scraps Parkinson's drug development after treatment fails mid-stage studyApril 17, 2024 | finance.yahoo.comSage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s DiseaseApril 16, 2024 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Hits New 1-Year Low at $15.06Sage Therapeutics (NASDAQ:SAGE) Hits New 52-Week Low at $15.06April 12, 2024 | marketbeat.comQ1 2024 EPS Estimates for Sage Therapeutics, Inc. (NASDAQ:SAGE) Raised by AnalystSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Leerink Partnrs increased their Q1 2024 earnings estimates for shares of Sage Therapeutics in a note issued to investors on Tuesday, April 9th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will post earApril 11, 2024 | businesswire.comSage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024April 5, 2024 | marketbeat.comVanguard Group Inc. Has $107.18 Million Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)Vanguard Group Inc. grew its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 3.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,208,002 shares of the biopha Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address A ‘DeFi Summer’ Projected! (Ad)Top analysts are predicting DeFi coins to see massive gains in the coming months… During this dubbed ‘DeFi Summer…’ A coin that has been called the “DeFi pioneer” is poised to shoot up 3-7x! Just click here to learn how you can access this coin right now. SAGE Media Mentions By Week SAGE Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAGE News Sentiment▼0.240.54▲Average Medical News Sentiment SAGE News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAGE Articles This Week▼34▲SAGE Articles Average Week Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Longboard Pharmaceuticals News Today Y-mAbs Therapeutics News Today SIGA Technologies News Today Arcturus Therapeutics News Today Cogent Biosciences News Today PureTech Health News Today Aurinia Pharmaceuticals News Today Pliant Therapeutics News Today Disc Medicine News Today Savara News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SAGE) was last updated on 5/17/2024 by MarketBeat.com Staff From Our Partners348 million Americans lives to END as we know it?The Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceGold Set to EXPLODE!Gold Safe ExchangeInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the Markets[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
